Dosage, dosage and usage of Telisotuzumab vedotin

Telisotuzumab vedotin (Telisotuzumab vedotin) is a targeted therapy drug mainly used to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high expression of c-Met protein. The usage and dosage of this drug have been determined through clinical studies. The recommended dose is 1.9 mg/kg, which should be infused intravenously every two weeks. For patients weighing more than 100kg, the maximum dose is limited to 190mg to avoid adverse reactions caused by overdose. Treatment should be continued until disease progression or the patient develops intolerable toxicity.

When usingEmrelis, the drug is administered by intravenous infusion, and the infusion time usually takes about 30 minutes. During the infusion process, medical staff need to closely monitor the patient's vital signs, paying special attention to possible allergic reactions or infusion-related reactions. Once serious adverse reactions are discovered, the infusion should be stopped immediately and corresponding treatment measures should be taken. Patients should undergo regular examinations during treatment, including tumor assessment and hematology monitoring, to evaluate treatment effects and detect potential side effects in a timely manner.

Before taking the medicine, the doctor will calculate the required dose based on the patient's weight and physical condition, and make precise preparations. Before starting treatment and before each medication, it should be confirmed whether the patient meets the treatment conditions, especially the expression level of c-Met protein. This drug is suitable for patients who have received systemic treatment but still have disease activity. Therefore, when taking the drug, an individualized treatment plan needs to be formulated based on the patient's specific condition. During the treatment process, patients should follow the doctor's instructions, perform infusions on time, and should not increase or decrease the dose at will or stop taking the medicine on their own.

In addition, patients should pay attention to following the guidance of their doctor when using Emrelis and reporting any symptoms of discomfort, especially reactions at the injection site, neurological symptoms or general discomfort. The doctor will adjust the treatment plan according to the patient's tolerance. If necessary, the medication may be suspended or the dosage may be adjusted to reduce side effects. Comprehensive management and close follow-up are the keys to ensuring treatment safety and improving efficacy. Through standardized use of Emrelis, patients can better control their disease, extend their survival, and improve their quality of life.

Reference materials:https://www.fda.gov/drugs/resources-information-approved-drugs